메뉴 건너뛰기




Volumn 75, Issue 1, 2016, Pages 311-315

Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN INHIBITOR OF ACTIVATED STAT3; STAT1 PROTEIN; STAT3 PROTEIN; STROMELYSIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TOFACITINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; AUTACOID; JANUS KINASE 3; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; STAT PROTEIN;

EID: 84954402415     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-207201     Document Type: Article
Times cited : (123)

References (19)
  • 1
    • 0037309635 scopus 로고    scopus 로고
    • Angiopoietins, growth factors, and vascular morphology in early arthritis
    • Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003;30:260268.
    • (2003) J Rheumatol , vol.30 , pp. 260268
    • Fearon, U.1    Griosios, K.2    Fraser, A.3
  • 2
    • 85018190193 scopus 로고    scopus 로고
    • Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features
    • Celis R, Planell N, Fernández-Sueiro JL, et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 2012;27:R9.
    • (2012) Arthritis Res Ther , vol.27 , pp. R9
    • Celis, R.1    Planell, N.2    Fernández-Sueiro, J.L.3
  • 3
    • 85172635853 scopus 로고    scopus 로고
    • PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, doubleblind, placebo-controlled SUMMIT 1 trial
    • McInnes IB, Kavanaugh A, Gottlieb AB, et al. PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, doubleblind, placebo-controlled SUMMIT 1 trial. Lancet 2013;382:7809.
    • (2013) Lancet , vol.382 , pp. 7809
    • McInnes, I.B.1    Kavanaugh, A.2    Gottlieb, A.B.3
  • 4
    • 84891898217 scopus 로고    scopus 로고
    • IL17A: A unique pathway in immune mediated diseases: Psoriasis, psoriatic arthritis, and rheumatoid arthritis
    • Kirkham BW, Kavanaugh A, Reich K. IL17A: a unique pathway in immune mediated diseases: psoriasis, psoriatic arthritis, and rheumatoid arthritis. Immunology 2014;141:13342.
    • (2014) Immunology , vol.141 , pp. 13342
    • Kirkham, B.W.1    Kavanaugh, A.2    Reich, K.3
  • 5
    • 84886951567 scopus 로고    scopus 로고
    • The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies
    • Novelli L, Chimenti MS, Chiricozzi A, et al. The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies. Autoimmun Rev 2013;13:001511.
    • (2013) Autoimmun Rev , vol.13 , pp. 001511
    • Novelli, L.1    Chimenti, M.S.2    Chiricozzi, A.3
  • 6
    • 0030765924 scopus 로고    scopus 로고
    • Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet?
    • O'Shea JJ. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 1997;7:11-13.
    • (1997) Immunity , vol.7 , pp. 11-13
    • O'Shea, J.J.1
  • 7
    • 79955027327 scopus 로고    scopus 로고
    • Modulation of innate and adaptive immune responses by tofacitinib (CP690,550)
    • Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP690,550). J Immunol 2011;7:4234-43.
    • (2011) J Immunol , vol.7 , pp. 4234-4243
    • Ghoreschi, K.1    Jesson, M.I.2    Li, X.3
  • 8
    • 84857239335 scopus 로고    scopus 로고
    • The JAK inhibitor CP690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: Autocrine role of type I interferon
    • Rosengren S, Corr M, Firestein GS, et al. The JAK inhibitor CP690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012;71:4407.
    • (2012) Ann Rheum Dis , vol.71 , pp. 4407
    • Rosengren, S.1    Corr, M.2    Firestein, G.S.3
  • 9
    • 84873188114 scopus 로고    scopus 로고
    • STAT1 expression and activation is increased in lesional psoriatic skin
    • Hald A, Andrés RM, Salskov Iversen ML, et al. STAT1 expression and activation is increased in lesional psoriatic skin. Br J Dermatol 2013;168: 302-10.
    • (2013) Br J Dermatol , vol.168 , pp. 302-310
    • Hald, A.1    Andrés, R.M.2    Salskov Iversen, M.L.3
  • 10
    • 84856459600 scopus 로고    scopus 로고
    • Podoplanin expression in wound and hyperproliferative psoriatic epidermis: Regulation by TGFβ and STAT3 activating cytokines, IFNγ, IL6, and IL22
    • Honma M, Minami Hori M, Takahashi H, et al. Podoplanin expression in wound and hyperproliferative psoriatic epidermis: regulation by TGFβ and STAT3 activating cytokines, IFNγ, IL6, and IL22. J Dermatol Sci 2012;65: 134-40.
    • (2012) J Dermatol Sci , vol.65 , pp. 134-140
    • Honma, M.1    Minami Hori, M.2    Takahashi, H.3
  • 11
    • 85018161888 scopus 로고    scopus 로고
    • The JAK inhibitor tofacitinib suppresses synovial JAK1STAT signalling in rheumatoid arthritis
    • Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015;71: 440-7.
    • (2015) Ann Rheum Dis , vol.71 , pp. 440-447
    • Boyle, D.L.1    Soma, K.2    Hodge, J.3
  • 12
    • 84893729220 scopus 로고    scopus 로고
    • JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T-helper17 expansion in psoriatic arthritis
    • Fiocco U, Accordi B, Martini V, et al. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T-helper17 expansion in psoriatic arthritis. Immunol Res 2014;58:61-9.
    • (2014) Immunol Res , vol.58 , pp. 61-69
    • Fiocco, U.1    Accordi, B.2    Martini, V.3
  • 13
    • 84868092910 scopus 로고    scopus 로고
    • Modulation of STAT3 in rheumatoid synovial T-cells suppresses Th17 differentiation and increases the proportion of Treg cells
    • Ju JH, Heo YJ, Cho ML, et al. Modulation of STAT3 in rheumatoid synovial T-cells suppresses Th17 differentiation and increases the proportion of Treg cells. Arthritis Rheum 2012;64:3543-52.
    • (2012) Arthritis Rheum , vol.64 , pp. 3543-3552
    • Ju, J.H.1    Heo, Y.J.2    Cho, M.L.3
  • 14
    • 84934985384 scopus 로고    scopus 로고
    • Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis
    • Gao W, McCormick J, Connolly M, et al. Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis. Ann Rheum Dis 2015;74:1275-83.
    • (2015) Ann Rheum Dis , vol.74 , pp. 1275-1283
    • Gao, W.1    McCormick, J.2    Connolly, M.3
  • 15
    • 79960889850 scopus 로고    scopus 로고
    • Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells
    • Akca H, Demiray A, Tokgun O, et al. Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells. Lung Cancer 2011;73:302-9.
    • (2011) Lung Cancer , vol.73 , pp. 302-309
    • Akca, H.1    Demiray, A.2    Tokgun, O.3
  • 16
    • 84897019848 scopus 로고    scopus 로고
    • Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo
    • Yokota K, Sato K, Miyazaki T, et al. Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheum 2014;66:121-9.
    • (2014) Arthritis Rheum , vol.66 , pp. 121-129
    • Yokota, K.1    Sato, K.2    Miyazaki, T.3
  • 17
    • 84867077631 scopus 로고    scopus 로고
    • JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production
    • LaBranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 2012;64:353-14.
    • (2012) Arthritis Rheum , vol.64 , pp. 353-414
    • LaBranche, T.P.1    Jesson, M.I.2    Radi, Z.A.3
  • 18
    • 84883588577 scopus 로고    scopus 로고
    • The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte derived dendritic cells
    • Kubo S, Yamaoka K, Kondo M, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte derived dendritic cells. Ann Rheum Dis 2014;73:219-28.
    • (2014) Ann Rheum Dis , vol.73 , pp. 219-228
    • Kubo, S.1    Yamaoka, K.2    Kondo, M.3
  • 19
    • 84861827087 scopus 로고    scopus 로고
    • The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin17 production by human CD4+ T cells
    • Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin17 production by human CD4+ T cells. Arthritis Rheum 2012;64:1790-8.
    • (2012) Arthritis Rheum , vol.64 , pp. 1790-1798
    • Maeshima, K.1    Yamaoka, K.2    Kubo, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.